MedTrace Logo

Efficacy and Safety of Wharton's Jelly-Derived Mesenchymal Stem Cell Exosomes in the Treatment of Diabetic Foot Ulcers: A Double-blinded Randomized Controlled Clinical Trial

NCT06812637 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2025-04-29

No results posted yet for this study

Summary

Study effeciency and safety of WJ-MSC derived exosomes in DFU healing

Conditions

  • Diabetic Foot Ulcer (DFU)
  • Exosomes

Interventions

DRUG

WJ-MSC- Exosomes

warton jelly derived mesenschymal stem cell derived exosomes dissolved in CMC

COMBINATION_PRODUCT

SOC (Standard of care)

Wound depridement for necrotic parts , local antibiotic , dressing , unloading

OTHER

Vehicle (placebo)

Vehicle for the MSC-EXO

Sponsors & Collaborators

  • Kafrelsheikh University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-06
Primary Completion
2024-06-06
Completion
2024-09-02

Countries

  • Egypt

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06812637 on ClinicalTrials.gov